Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WXI9
UPID:
P66B_HUMAN
Alternative names:
GATA zinc finger domain-containing protein 2B; p66/p68
Alternative UPACC:
Q8WXI9; D3DUZ2; Q5VUR2; Q7LG68; Q9ULS0
Background:
Transcriptional repressor p66-beta, also known as GATA zinc finger domain-containing protein 2B, plays a pivotal role in chromatin remodeling as part of the histone deacetylase NuRD complex. It enhances MBD2-mediated repression and is essential for targeting MBD3 to specific nuclear loci. Its involvement in synapse development underscores its importance in neurological processes.
Therapeutic significance:
Linked to Gand syndrome, a condition marked by developmental delays, intellectual impairment, and dysmorphic features, p66-beta's genetic variants offer a target for therapeutic intervention. Understanding its role could pave the way for novel treatments for Gand syndrome and related neurological disorders.